Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 NH7WS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXZZVVKSzVyPUCuNFAxODNzNzFOwG0> MVPTRW5ITVJ?
SK-MEL-30 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fmPWlEPTB;MD6wNFA{PTVizszN NEDyW2dUSU6JRWK=
NALM-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jDXWlEPTB;MD6wNFA{PTZizszN NEXhNZVUSU6JRWK=
KYSE-450 M{m0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzMRZhKSzVyPUCuNFAxPDZ7IN88US=> NX3hW3lZW0GQR1XS
BHY M3vMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n6fGlEPTB;MD6wNFA3ODFizszN NFXaOXFUSU6JRWK=
GR-ST MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqUWlEPTB;MD6wNFA3PDhizszN MYDTRW5ITVJ?
786-0 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfx[oNVUUN3ME2wMlAxODd5NjFOwG0> MkLwV2FPT0WU
C-33-A NH:z[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ryVGlEPTB;MD6wNFA5PDhizszN MojsV2FPT0WU
BHT-101 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITi[|NKSzVyPUCuNFAyODZizszN MnLwV2FPT0WU
EB2 M37Ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrkUJBnUUN3ME2wMlAxOTF6IN88US=> NHjh[XVUSU6JRWK=
G-361 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICweppKSzVyPUCuNFAyOjRizszN M2HuR3NCVkeHUh?=
KE-37 M1Lxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHxTWM2OD1yLkCwNVI5KM7:TR?= M4HZb3NCVkeHUh?=
MHH-PREB-1 NWOzd2VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHlcZFKSzVyPUCuNFAyPCEQvF2= NVHMSYJKW0GQR1XS
MCF7 NVTwNY8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMECxOVkh|ryP M1yzenNCVkeHUh?=
LOUCY MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\3TWM2OD1yLkCwNVc2KM7:TR?= MnjKV2FPT0WU
EW-7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCPJhKSzVyPUCuNFAyPzVizszN NUPxU3lsW0GQR1XS
KYSE-510 M4O0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMECyN|Mh|ryP NF61NWZUSU6JRWK=
SK-MEL-3 NIq1OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMECyOlQh|ryP NG\ob4lUSU6JRWK=
HAL-01 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX2TWM2OD1yLkCwNlk4KM7:TR?= MWfTRW5ITVJ?
HCC2998 NWfib5ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMECzN|Uh|ryP M4P1enNCVkeHUh?=
A375 NWPLNYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi4R2pKSzVyPUCuNFA{PSEQvF2= MYnTRW5ITVJ?
MZ7-mel MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPHTHUyUUN3ME2wMlAxOzl7IN88US=> NXPT[GZLW0GQR1XS
SH-4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nOTGlEPTB;MD6wNFQyPyEQvF2= M1u0OnNCVkeHUh?=
HT-144 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfsWYduUUN3ME2wMlAxPDNizszN MXrTRW5ITVJ?
KYSE-140 NWn4WGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEC0N|Uh|ryP MkP5V2FPT0WU
PSN1 M1nzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEC0Olch|ryP Mn\DV2FPT0WU
COLO-679 NHPkPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[4TWM2OD1yLkCwOFk5KM7:TR?= M3;YbHNCVkeHUh?=
SW620 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfkUGp6UUN3ME2wMlAxPTFzIN88US=> M{nyWHNCVkeHUh?=
HGC-27 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEC1NlQh|ryP NVvGfVZWW0GQR1XS
IGROV-1 NXP3eXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vTVGlEPTB;MD6wNFYh|ryP NF;xeGxUSU6JRWK=
IGR-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEC2NFEh|ryP MkLjV2FPT0WU
EW-1 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPSUY4zUUN3ME2wMlAxPjVzIN88US=> MnXNV2FPT0WU
769-P NIDkdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEC2O|gh|ryP MVXTRW5ITVJ?
HN NVXicW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP1TWM2OD1yLkCwOlc6KM7:TR?= M37VdHNCVkeHUh?=
SIG-M5 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlSwTWM2OD1yLkCwO|Eh|ryP M17i[HNCVkeHUh?=
IST-MEL1 NVq0cZByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3HVHFVUUN3ME2wMlAxQDF6IN88US=> MnHtV2FPT0WU
ST486 NEK1VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTGTWM2OD1yLkCwPFI2KM7:TR?= MXXTRW5ITVJ?
ES7 NWDOZ3V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEC4OFYh|ryP Mo\hV2FPT0WU
GAK MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vCbmlEPTB;MD6wNFg1QCEQvF2= M{\Xd3NCVkeHUh?=
BB30-HNC NUDVfVd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvBTWM2OD1yLkCwPFU5KM7:TR?= MlrqV2FPT0WU
IPC-298 M1zlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjRVGlKSzVyPUCuNFA6OjdizszN MnvRV2FPT0WU
NKM-1 M1r4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\uWGlEPTB;MD6wNFk4OiEQvF2= M4jCbnNCVkeHUh?=
RKO NXPUTGJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HSXWlEPTB;MD6wNVA1PCEQvF2= M1GyNHNCVkeHUh?=
ACN MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXsN|hYUUN3ME2wMlAyOTNzIN88US=> M{XheXNCVkeHUh?=
SW1417 M3q3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnPOIZ[UUN3ME2wMlAyOjJ3IN88US=> MnLlV2FPT0WU
SR NWr2TJJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvVTWM2OD1yLkCxNlM2KM7:TR?= M3LnRXNCVkeHUh?=
SNG-M MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEGzNVch|ryP NVfa[5U4W0GQR1XS
CAL-12T NGDkVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TMUmlEPTB;MD6wNVM1PiEQvF2= NVTOZ4tCW0GQR1XS
HSC-3 NXzVe|ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\SZVZsUUN3ME2wMlAyOzV3IN88US=> NYjsTY9PW0GQR1XS
DOHH-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HZfWlEPTB;MD6wNVQyOiEQvF2= M2HISHNCVkeHUh?=
NB69 NXfHdWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnaTWM2OD1yLkCxOVY2KM7:TR?= NIL2ZmlUSU6JRWK=
LC-2-ad NHnHOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHLTWM2OD1yLkCxOVgyKM7:TR?= Mn\rV2FPT0WU
RVH-421 M3XPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfJVFFKSzVyPUCuNFE3PzRizszN MY\TRW5ITVJ?
TGW NVf2[G1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jsR2lEPTB;MD6wNVc{QSEQvF2= MnX3V2FPT0WU
HCC1569 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD1yLkCxO|k4KM7:TR?= MXHTRW5ITVJ?
CAL-85-1 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEG4N|Ih|ryP MkD2V2FPT0WU
RPMI-8402 M3TlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT5WGhtUUN3ME2wMlAyQDV6IN88US=> MnPvV2FPT0WU
THP-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PCcWlEPTB;MD6wNVk6QCEQvF2= MnfoV2FPT0WU
ONS-76 M{m0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2cGlEPTB;MD6wNlA{PiEQvF2= NYT1[G5vW0GQR1XS
A2780 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELQ[3VKSzVyPUCuNFIxPzlizszN M4C4UHNCVkeHUh?=
RPMI-2650 NVLk[|dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviTWM2OD1yLkCyNlk3KM7:TR?= NEfJXJFUSU6JRWK=
MEL-HO M1TS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXOTWM2OD1yLkCyN|Q5KM7:TR?= Mmr0V2FPT0WU
MC-CAR NFSxd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTEc|ZJUUN3ME2wMlAzOzV4IN88US=> NFKzNGFUSU6JRWK=
HSC-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTwTWM2OD1yLkCyOFY3KM7:TR?= NIjkd2dUSU6JRWK=
MEL-JUSO MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fjXWlEPTB;MD6wNlQ4OyEQvF2= M4PGO3NCVkeHUh?=
CAL-62 NFrIbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjKb4Z{UUN3ME2wMlAzPjB{IN88US=> MojKV2FPT0WU
DMS-273 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEK4OFch|ryP NXj4S4tGW0GQR1XS
S-117 NEjMZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInzfI1KSzVyPUCuNFI6ODZizszN MW\TRW5ITVJ?
SUP-T1 NV[1TJhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEK5OFkh|ryP MljTV2FPT0WU
MZ2-MEL Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTYTWM2OD1yLkCyPVU6KM7:TR?= MlrjV2FPT0WU
KYSE-270 NH\tVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEK5O|Yh|ryP MlTqV2FPT0WU
CMK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LoVmlEPTB;MD6wN|AzOyEQvF2= M132c3NCVkeHUh?=
8505C NIrsc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPmTWM2OD1yLkCzNFQh|ryP NVvReHN2W0GQR1XS
NUGC-3 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfoVIRGUUN3ME2wMlA{ODR6IN88US=> NIjZS2dUSU6JRWK=
A101D NYrvNnBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEOwOVUh|ryP NUf4cZM6W0GQR1XS
G-401 NF63UIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPoTWM2OD1yLkCzNFk{KM7:TR?= M4D1OnNCVkeHUh?=
OVCAR-8 NH\McZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5TWM2OD1yLkCzNVA4KM7:TR?= NX62eXNHW0GQR1XS
IMR-5 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTSbJhKSzVyPUCuNFMzPDRizszN NEWzSWdUSU6JRWK=
DoTc2-4510 NFXmW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEOzPVMh|ryP MnGwV2FPT0WU
HOS NGHHO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYryXXBtUUN3ME2wMlA{PDd|IN88US=> NX;hfZRZW0GQR1XS
HEC-1 M1nkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEO2PEDPxE1? MXLTRW5ITVJ?
SW756 NYj5WGl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;2fGlEPTB;MD6wN|gzOSEQvF2= NH;RdHVUSU6JRWK=
NCI-H64 M3rEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEO4OFIh|ryP MmnXV2FPT0WU
EW-16 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEO5NFkh|ryP NEDjPZhUSU6JRWK=
CAL-51 NUfaS5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMESwNFUh|ryP MV;TRW5ITVJ?
KYSE-150 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvnTWM2OD1yLkC0NFEyKM7:TR?= MU\TRW5ITVJ?
SW1710 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMESwNVgh|ryP Mn;xV2FPT0WU
HuP-T4 NYjIN4FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMESxNVgh|ryP M1fseHNCVkeHUh?=
LB373-MEL-D MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrRSnFKSzVyPUCuNFQzOzJizszN MXjTRW5ITVJ?
EW-13 NIjCToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\6Z2lEPTB;MD6wOFQxPiEQvF2= MVLTRW5ITVJ?
HT-29 M4fU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne4TWM2OD1yLkC0OFkh|ryP NFW4[5dUSU6JRWK=
SCC-25 NUnNSGJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWxTWM2OD1yLkC0OFk1KM7:TR?= M4q3cXNCVkeHUh?=
REH MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMES2N|Uh|ryP MWPTRW5ITVJ?
L-363 M1HLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMES2O|kh|ryP NV\3d2xEW0GQR1XS
NCI-H1770 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPnd294UUN3ME2wMlA1Pjl5IN88US=> NH7tNWhUSU6JRWK=
CHL-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMES4OVch|ryP M1nCZXNCVkeHUh?=
ES1 NIe4cllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojlTWM2OD1yLkC0PFg2KM7:TR?= NYWwNHVxW0GQR1XS
SCC-15 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ZTWM2OD1yLkC0PVAzKM7:TR?= M{\pPXNCVkeHUh?=
MRK-nu-1 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMES5N|Yh|ryP M{jveXNCVkeHUh?=
PF-382 NUDtNFZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMES5N|kh|ryP MVTTRW5ITVJ?
COLO-680N MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEWwOFch|ryP NEjVOVNUSU6JRWK=
LK-2 M3LXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HyNGlEPTB;MD6wOVA3OyEQvF2= Ml;2V2FPT0WU
NCI-H2342 M{jGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEWxNVch|ryP M1TNSHNCVkeHUh?=
HMV-II MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG1SXZKSzVyPUCuNFUzOzlizszN NEi4OmJUSU6JRWK=
PC-14 NIjxNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLZ[JNWUUN3ME2wMlA2OjV{IN88US=> NUXFOlRyW0GQR1XS
COLO-320-HSR NWjjc2VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEWyPFkh|ryP MlHkV2FPT0WU
697 NEjTWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEWzNlMh|ryP MmDCV2FPT0WU
NEC8 NYrhTWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfPTWM2OD1yLkC1OVkh|ryP NIDpWmZUSU6JRWK=
LCLC-97TM1 NGXwN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEW1PVQh|ryP MUjTRW5ITVJ?
Daoy M3zacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEW2NVYh|ryP NIH3SpZUSU6JRWK=
ETK-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uzZmlEPTB;MD6wOVY4OiEQvF2= MWPTRW5ITVJ?
A388 M{XySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T6WmlEPTB;MD6wOVY6PSEQvF2= NIrMfYRUSU6JRWK=
COLO-205 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfaSo1KSzVyPUCuNFU4OTZizszN NVPucpBqW0GQR1XS
SK-PN-DW MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[1WmlEPTB;MD6wOVczQSEQvF2= NILMR2pUSU6JRWK=
SF268 NFrsfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEW3OVYh|ryP MnXvV2FPT0WU
OCI-AML2 NFXPcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDiSpNRUUN3ME2wMlA2Pzd5IN88US=> MVzTRW5ITVJ?
GAMG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlPWRKSzVyPUCuNFU5KM7:TR?= NF;O[oNUSU6JRWK=
BCPAP NXLic2JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPLPI9HUUN3ME2wMlA2QDl{IN88US=> NFrLfW5USU6JRWK=
BC-1 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLkTWM2OD1yLkC2NFIzKM7:TR?= M1mzd3NCVkeHUh?=
IA-LM MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzkeJZkUUN3ME2wMlA3ODV|IN88US=> NGrDSoVUSU6JRWK=
NCI-H1299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PSNWlEPTB;MD6wOlE{KM7:TR?= M3zGUHNCVkeHUh?=
COR-L23 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrXZmNKSzVyPUCuNFYyOzRizszN NITiWpVUSU6JRWK=
KYSE-180 NHXuXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn1cXQ5UUN3ME2wMlA3OTR{IN88US=> MlrxV2FPT0WU
LOXIMVI NEjhcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:3cJpKSzVyPUCuNFYyQDhizszN MmTMV2FPT0WU
BL-41 NX\XUYt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\lW3BEUUN3ME2wMlA3OjF7IN88US=> Mn7sV2FPT0WU
BL-70 NET6eFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwME[zNFIh|ryP NWLVWFM6W0GQR1XS
NOS-1 M{TCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD1yLkC2OFEyKM7:TR?= MV3TRW5ITVJ?
NB13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m2TGlEPTB;MD6wOlQzOSEQvF2= Ml\CV2FPT0WU
CAL-27 NXL6ZWUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jWS2lEPTB;MD6wOlQ3PCEQvF2= NF;kUYRUSU6JRWK=
CA46 NHzPd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzmTWM2OD1yLkC2OVM4KM7:TR?= MYPTRW5ITVJ?
SW962 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HjOGlEPTB;MD6wOlU3QSEQvF2= MmfsV2FPT0WU
NCI-H226 NY\JVmR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfUTWM2OD1yLkC2OlMzKM7:TR?= NGfDV21USU6JRWK=
KYSE-70 NELNNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PZ[2lEPTB;MD6wOlk1PSEQvF2= NW\6PGM4W0GQR1XS
Daudi MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLMTWM2OD1yLkC3NFgyKM7:TR?= NEHGRoFUSU6JRWK=
SW626 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml71TWM2OD1yLkC3NlA1KM7:TR?= MYLTRW5ITVJ?
ESS-1 M{LCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEeyOFYh|ryP M17ZVnNCVkeHUh?=
YT NGPXRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjLZXFSUUN3ME2wMlA4OzR3IN88US=> NFTKXpRUSU6JRWK=
P12-ICHIKAWA NIK1W|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEezOFkh|ryP NV\lc3EzW0GQR1XS
BxPC-3 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnFeYxFUUN3ME2wMlA4PDV6IN88US=> MmjXV2FPT0WU
CTV-1 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jPbWlEPTB;MD6wO|UyPyEQvF2= NHfURppUSU6JRWK=
MLMA M1fyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ReGlEPTB;MD6wO|U{PCEQvF2= NHXGN5pUSU6JRWK=
WSU-NHL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEe1OVQh|ryP MoPnV2FPT0WU
CTB-1 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mwemlEPTB;MD6wO|U5QCEQvF2= M1TnUnNCVkeHUh?=
MMAC-SF MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEe2Olgh|ryP NHvITHFUSU6JRWK=
8-MG-BA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjJNVBsUUN3ME2wMlA4QDBzIN88US=> M4i5OnNCVkeHUh?=
NCI-H358 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHTTWM2OD1yLkC3PFc6KM7:TR?= MoHqV2FPT0WU
BFTC-905 NXTlWJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TtbWlEPTB;MD6wO|kxQSEQvF2= NVrHZpNLW0GQR1XS
NCI-H727 NGDieWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjZ[G9yUUN3ME2wMlA5ODV|IN88US=> M{jaW3NCVkeHUh?=
CHP-212 NFf6SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEiwPVUh|ryP NHjnOHpUSU6JRWK=
HOP-62 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGwcZhKSzVyPUCuNFgzPDVizszN NXPhbHk{W0GQR1XS
CESS Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M324fmlEPTB;MD6wPFI3QSEQvF2= Mnf4V2FPT0WU
HuCCT1 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLXSFFTUUN3ME2wMlA5OzN|IN88US=> MmC4V2FPT0WU
DEL M2f2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHhVFlKSzVyPUCuNFg{PDdizszN M{Psc3NCVkeHUh?=
5637 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKybW5KSzVyPUCuNFg{PjdizszN NEPjNIVUSU6JRWK=
RS4-11 M2\Yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEi0PVch|ryP NWX2W21[W0GQR1XS
KURAMOCHI NU\hNFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPbWlEPTB;MD6wPFUxQSEQvF2= NX3JOZNsW0GQR1XS
A427 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyzbHVKSzVyPUCuNFg2OTJizszN M1;RZnNCVkeHUh?=
A3-KAW NE[1V4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjfHBLUUN3ME2wMlA5PTZ4IN88US=> MULTRW5ITVJ?
LS-123 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEi3NVkh|ryP NWr1VmJiW0GQR1XS
LoVo MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj4VFlKSzVyPUCuNFg4OiEQvF2= M1:3c3NCVkeHUh?=
PA-1 NH\udYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfQN3ZKSzVyPUCuNFg4PjlizszN NV65TWdzW0GQR1XS
CP50-MEL-B NXjoXWpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rQd2lEPTB;MD6wPFc6OyEQvF2= MlmyV2FPT0WU
A431 NXj3bFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[zN3JKSzVyPUCuNFg5ODFizszN NVqx[m83W0GQR1XS
HCT-116 NEHLRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTqZVBWUUN3ME2wMlA5QDB{IN88US=> M3;uRXNCVkeHUh?=
A4-Fuk NY\Rc25RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnY[|VOUUN3ME2wMlA5QTR5IN88US=> MlnyV2FPT0WU
RPMI-6666 NHG4[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEi5Olch|ryP M{K3[3NCVkeHUh?=
Calu-6 M{nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zESWlEPTB;MD6wPVAzQSEQvF2= MXHTRW5ITVJ?
KMOE-2 NXjB[mNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i0NWlEPTB;MD6wPVA{QSEQvF2= NU\kclU4W0GQR1XS
A704 NHHUPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLGTWM2OD1yLkC5NVUh|ryP M2HP[3NCVkeHUh?=
HO-1-N-1 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXjTWM2OD1yLkC5NlQ6KM7:TR?= M2\nSnNCVkeHUh?=
NCI-H2122 NGS5fYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITKOIRKSzVyPUCuNFk{PzhizszN MX\TRW5ITVJ?
U-698-M NFXTbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW1cYNKSzVyPUCuNFk1ODlizszN NEnGUohUSU6JRWK=
IST-SL2 M1;YUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCzTWM2OD1yLkC5OFY5KM7:TR?= NUPvVIpPW0GQR1XS
TE-10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK0TIZKSzVyPUCuNFk2QDRizszN NILFS5NUSU6JRWK=
PANC-03-27 NH3sT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEm2O|Eh|ryP NWL6S5RpW0GQR1XS
KYSE-410 M2nkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInve|VKSzVyPUCuNFk4QTdizszN M4TXUnNCVkeHUh?=
TE-8 NWO2do85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHlW4d4UUN3ME2wMlA6QDh3IN88US=> MlrXV2FPT0WU
MN-60 NX;2fGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PCTWlEPTB;MD6wPVg6PyEQvF2= MlOyV2FPT0WU
NCI-H460 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMUCwPUDPxE1? MnLJV2FPT0WU
LB771-HNC NUHRWFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnFTIdKSzVyPUCuNVAzPTVizszN M125[HNCVkeHUh?=
ES4 NUPWS205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMUCyOlQh|ryP MUjTRW5ITVJ?
HUTU-80 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nUdWlEPTB;MD6xNFM3PSEQvF2= NUXhTHJWW0GQR1XS
647-V NVLVe5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMUC0NFgh|ryP MnT6V2FPT0WU
HTC-C3 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDTZoNKSzVyPUCuNVA1OzJizszN NX[yR|BKW0GQR1XS
NTERA-S-cl-D1 NFm2Z5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjVTWM2OD1yLkGwOFQ5KM7:TR?= MnrDV2FPT0WU
A2058 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jD[mlEPTB;MD6xNFY2PSEQvF2= NIm5c|VUSU6JRWK=
MZ1-PC MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMUC4N{DPxE1? NETYT|lUSU6JRWK=
J82 NYnseHkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\EdmZrUUN3ME2wMlExQDh2IN88US=> MoTWV2FPT0WU
ARH-77 NEjze3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDj[VhsUUN3ME2wMlEyKM7:TR?= M{eyRnNCVkeHUh?=
Ca9-22 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTmfWhZUUN3ME2wMlEyOTJ6IN88US=> NUHOW|kyW0GQR1XS
NCI-H1648 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW2VW9MUUN3ME2wMlEyOjh4IN88US=> MV;TRW5ITVJ?
MC116 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMUGzN|ch|ryP MX3TRW5ITVJ?
EoL-1-cell MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M333VGlEPTB;MD6xNVQ3PyEQvF2= NIi1fGlUSU6JRWK=
PANC-10-05 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXnTWM2OD1yLkGxOFkyKM7:TR?= MlnjV2FPT0WU
SF539 NUD4dWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TjfGlEPTB;MD6xNVYyPiEQvF2= NVe1dVdEW0GQR1XS
ES8 NV3JW5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD1yLkGxOlM{KM7:TR?= NHj4e2dUSU6JRWK=
NCI-H810 NYnEOllnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfYOnZKSzVyPUCuNVE3PjRizszN MVfTRW5ITVJ?
J-RT3-T3-5 M2PPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkbmRKSzVyPUCuNVE4PSEQvF2= MX7TRW5ITVJ?
NY MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUG4NVch|ryP Mm\wV2FPT0WU
NCI-SNU-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH1UI5KSzVyPUCuNVIyPDhizszN M4DWcXNCVkeHUh?=
EFM-19 NFq1W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMUKzO|Qh|ryP MVTTRW5ITVJ?
HCC1806 NHvoUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPSOG5yUUN3ME2wMlEzOzh|IN88US=> M3LYeHNCVkeHUh?=
HCE-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXaVXMzUUN3ME2wMlEzPTNzIN88US=> M2LQTHNCVkeHUh?=
HT-1376 NGnBXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHwTWM2OD1yLkGyOlY5KM7:TR?= MYXTRW5ITVJ?
BE-13 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMUK4OlYh|ryP NY\VTXNbW0GQR1XS
NCI-H520 NVH0THlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5OmRKSzVyPUCuNVI5PjdizszN MnXBV2FPT0WU
SK-MES-1 NFTHbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQblhKSzVyPUCuNVI6OTNizszN Mn\qV2FPT0WU
SNU-423 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v3emlEPTB;MD6xNlkyPCEQvF2= NUXGVpV[W0GQR1XS
Ramos-2G6-4C10 NHvvd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnX[Zg3UUN3ME2wMlEzQTF4IN88US=> M4rGWnNCVkeHUh?=
EW-18 M37rO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\BTWM2OD1yLkGzNFI3KM7:TR?= NHTt[mRUSU6JRWK=
NCI-H2087 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDpSWJ6UUN3ME2wMlE{ODJ5IN88US=> M3TxeXNCVkeHUh?=
COLO-792 NH7NSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\aeplKUUN3ME2wMlE{OTZ3IN88US=> MorvV2FPT0WU
QIMR-WIL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LQeGlEPTB;MD6xN|IzOyEQvF2= NEDPS|hUSU6JRWK=
ACHN MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3WSYdKSzVyPUCuNVMzPDdizszN NVL6VXhqW0GQR1XS
RPMI-8866 NGHkNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jve2lEPTB;MD6xN|I3OSEQvF2= NX2zd3J[W0GQR1XS
SK-LU-1 NF6zeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIUoRKSzVyPUCuNVM1PDlizszN NU\BfWpiW0GQR1XS
SK-UT-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTUeYQ2UUN3ME2wMlE{PjJ6IN88US=> NES5V2ZUSU6JRWK=
MFE-296 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLPTWM2OD1yLkGzPFY1KM7:TR?= Mnr4V2FPT0WU
RD NEHje4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMUO5PVch|ryP NY\6Z5prW0GQR1XS
LS-411N NWG2do11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3THOWlEPTB;MD6xOFI6PSEQvF2= NIH5T2JUSU6JRWK=
NCI-H747 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5ZWlEPTB;MD6xOFMh|ryP MlrqV2FPT0WU
ES6 M1npZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\LRVdKSzVyPUCuNVQ{PiEQvF2= MkL0V2FPT0WU
TE-1 NHrVVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHnZ5NmUUN3ME2wMlE1PDB5IN88US=> M4LLbXNCVkeHUh?=
SJSA-1 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELvflFKSzVyPUCuNVQ4ODdizszN NFj4NopUSU6JRWK=
NCI-H1355 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXIZVV{UUN3ME2wMlE2Ojl|IN88US=> M37ZOnNCVkeHUh?=
HEL M2\m[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnzW|hGUUN3ME2wMlE2PDR5IN88US=> MmDYV2FPT0WU
639-V NX7jTGN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMUW1PVYh|ryP NV;TXXdbW0GQR1XS
AN3-CA NETwSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvxR3BKSzVyPUCuNVU3OzlizszN MX;TRW5ITVJ?
SK-MEL-2 M2Lhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf3TWM2OD1yLkG1OlY5KM7:TR?= NFPJNVBUSU6JRWK=
SW872 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMU[wOFIh|ryP M4Dx[HNCVkeHUh?=
DU-4475 M3y4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLye3pKSzVyPUCuNVYyPjJizszN M33IXHNCVkeHUh?=
YKG-1 M37iOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLwd2k1UUN3ME2wMlE3Ojd|IN88US=> MX\TRW5ITVJ?
GT3TKB NWXkfHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMU[yPFMh|ryP NIDPW2FUSU6JRWK=
GB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;USYRDUUN3ME2wMlE3PDJ2IN88US=> MlzQV2FPT0WU
KARPAS-422 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn3SnNKSzVyPUCuNVY2PzRizszN NEHUfZVUSU6JRWK=
ATN-1 M2nxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMU[2OVYh|ryP NELZR5pUSU6JRWK=
HLE NGP0[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMU[4O|ch|ryP Mom5V2FPT0WU
D-542MG MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5NopKSzVyPUCuNVY6QDZizszN MkHuV2FPT0WU
EB-3 NE\2UYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUezNUDPxE1? M3fPXHNCVkeHUh?=
HCC1143 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X2TWlEPTB;MD6xO|M6PiEQvF2= NXPLXG14W0GQR1XS
DJM-1 NYHDcWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PLcWlEPTB;MD6xO|Q2OSEQvF2= NV3JSVJrW0GQR1XS
BT-474 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT3UHhKSzVyPUCuNVc1QDlizszN NI\iPYtUSU6JRWK=
BB65-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELPdlhKSzVyPUCuNVc2PDVizszN Mmr3V2FPT0WU
NCI-H292 NFzGb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV31V45XUUN3ME2wMlE4PjBzIN88US=> M1y2VHNCVkeHUh?=
MKN28 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XGXmlEPTB;MD6xO|Y2OyEQvF2= M1;a[nNCVkeHUh?=
TK10 NYrzd5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMUe3NFIh|ryP MnOzV2FPT0WU
TYK-nu MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe0XFdKSzVyPUCuNVc6PDlizszN NW[xTYZsW0GQR1XS
8305C NXvoO3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaZoNKSzVyPUCuNVc6PzFizszN MWTTRW5ITVJ?
MV-4-11 NGHTd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LoWWlEPTB;MD6xO|k4PyEQvF2= M3f2PXNCVkeHUh?=
NCI-H522 M3XMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMUiwPVQh|ryP M2\u[nNCVkeHUh?=
Hs-578-T NEjU[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\BRpNuUUN3ME2wMlE5Ojl{IN88US=> Mm[zV2FPT0WU
LCLC-103H M{nHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\x[mlEPTB;MD6xPFUzPyEQvF2= M4HSWHNCVkeHUh?=
MHH-ES-1 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqyN29KSzVyPUCuNVg3OjlizszN NY\F[2NSW0GQR1XS
NCI-H441 NF[0XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDZTWM2OD1yLkG5NVQ5KM7:TR?= MW\TRW5ITVJ?
AM-38 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMUmyNlUh|ryP MWXTRW5ITVJ?
SW1783 NEPJ[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjMTWM2OD1yLkG5N|A2KM7:TR?= NGTGe4lUSU6JRWK=
SK-HEP-1 NIPrXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMUm2N|ch|ryP M4jheHNCVkeHUh?=
OAW-28 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjsUoR3UUN3ME2wMlIxOTd6IN88US=> MYjTRW5ITVJ?
TE-15 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMkCyOVIh|ryP MV;TRW5ITVJ?
HCE-4 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMkCyPFQh|ryP Ml7EV2FPT0WU
JiyoyeP-2003 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTRSXFnUUN3ME2wMlIxOzN4IN88US=> MoLuV2FPT0WU
OVCAR-4 NVywTWJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD1SpVKSzVyPUCuNlA3OjhizszN M2nWSnNCVkeHUh?=
SNU-449 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\rU5ZzUUN3ME2wMlIxPzl5IN88US=> Ml;0V2FPT0WU
SBC-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkGyNVUh|ryP MlfnV2FPT0WU
T84 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrJboVKSzVyPUCuNlEzPDhizszN MVrTRW5ITVJ?
LP-1 M17lNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDnVZJKSzVyPUCuNlE{ODJizszN M375eHNCVkeHUh?=
MG-63 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3zTWM2OD1yLkKxN|gzKM7:TR?= MYDTRW5ITVJ?
OAW-42 NFOzO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLrTIZKSzVyPUCuNlE1PzhizszN M{L1TXNCVkeHUh?=
L-540 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMkG1PVgh|ryP MnO0V2FPT0WU
RH-1 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHlN4w2UUN3ME2wMlIzOjR{IN88US=> M3;UcXNCVkeHUh?=
HCT-15 MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP0TWM2OD1yLkKyOFg1KM7:TR?= MU\TRW5ITVJ?
OCUB-M M{fXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;3TppKSzVyPUCuNlI1QDhizszN M{LmSnNCVkeHUh?=
GP5d M1OwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHqTWM2OD1yLkKyOVI5KM7:TR?= MljXV2FPT0WU
NCI-H2030 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjTTYlKSzVyPUCuNlI4OzRizszN NYXrboQ6W0GQR1XS
ML-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[0TWM2OD1yLkKyPFg6KM7:TR?= NI\NbYNUSU6JRWK=
CAL-39 NIO4codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjjOHZKSzVyPUCuNlI6OzZizszN MXXTRW5ITVJ?
MIA-PaCa-2 NXPNUJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELoNZFKSzVyPUCuNlMzQDdizszN MUTTRW5ITVJ?
TE-9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTwPJdmUUN3ME2wMlI{OzJizszN NIXufZJUSU6JRWK=
LB2518-MEL Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;xdXROUUN3ME2wMlI{Ozd{IN88US=> NVi1NItGW0GQR1XS
DB NHT4dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\jbZRKSzVyPUCuNlM1OzhizszN NIDlR4RUSU6JRWK=
NCI-H596 NXLFfm5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHpTWM2OD1yLkKzOVcyKM7:TR?= NUHIOYIxW0GQR1XS
SW1990 NVXMTIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TCO2lEPTB;MD6yN|k1PiEQvF2= NFnLUJhUSU6JRWK=
P30-OHK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m0UmlEPTB;MD6yOFA2KM7:TR?= NFe3bIxUSU6JRWK=
ALL-PO NVrTSFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMkSxOlkh|ryP NH32VopUSU6JRWK=
Saos-2 NEXwOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjt[plWUUN3ME2wMlI1PTdzIN88US=> MWLTRW5ITVJ?
MFH-ino M{HwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDyUYV4UUN3ME2wMlI1Pjl{IN88US=> MVjTRW5ITVJ?
OE33 M1mzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMkWxNUDPxE1? NIrCOXBUSU6JRWK=
Calu-3 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\4UWlEPTB;MD6yOVI6PyEQvF2= M2rqdXNCVkeHUh?=
HT NVztfXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXDVG9KSzVyPUCuNlU3OjFizszN MoLEV2FPT0WU
LXF-289 NUHLOVh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMkW5PFQh|ryP NHm2OGdUSU6JRWK=
KGN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMk[wPFkh|ryP NHrNR3hUSU6JRWK=
NCI-H1417 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojQTWM2OD1yLkK2OVI1KM7:TR?= NVzvRmJ[W0GQR1XS
SF126 NXLYNWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\ZVmlNUUN3ME2wMlI4OzB{IN88US=> NHS5XHJUSU6JRWK=
SAS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;4XmlEPTB;MD6yO|MxQCEQvF2= M1jSRXNCVkeHUh?=
22RV1 NVrnfIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMkezO|gh|ryP NHTVS|lUSU6JRWK=
GI-1 M2fMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LIO2lEPTB;MD6yO|Q5PyEQvF2= MoPrV2FPT0WU
ES3 M1XUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX0c2hPUUN3ME2wMlI4PzZ|IN88US=> MV7TRW5ITVJ?
NB1 M2fLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW2ZohKSzVyPUCuNlc5PzZizszN MXHTRW5ITVJ?
NCI-H650 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljQTWM2OD1yLkK4N|AzKM7:TR?= MnjZV2FPT0WU
IST-MES1 M2L5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\6cFQ{UUN3ME2wMlI5PTV2IN88US=> Mo\4V2FPT0WU
UM-UC-3 NIHqVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LQWGlEPTB;MD6yPVE1KM7:TR?= MXLTRW5ITVJ?
CAL-120 NVLPZ5dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMkm2N|Eh|ryP NFj2XWVUSU6JRWK=
UACC-62 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHYVoFIUUN3ME2wMlMxOjRzIN88US=> MWHTRW5ITVJ?
TE-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnD[4JYUUN3ME2wMlMxOjR7IN88US=> NUjFdJl1W0GQR1XS
MKN1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXSVppDUUN3ME2wMlMxOzZizszN NH31RVZUSU6JRWK=
KS-1 NWftUmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwM{C1NlYh|ryP NHrrO4ZUSU6JRWK=
GCIY NXjPVmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwM{GwNFIh|ryP NV3JfHhOW0GQR1XS
OVCAR-5 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\5[GlEPTB;MD6zNVExPiEQvF2= M37lNXNCVkeHUh?=
U-266 M3nIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwM{GxOFch|ryP NIX4dmFUSU6JRWK=
Calu-1 NHfhUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfYUmJJUUN3ME2wMlMyOjh7IN88US=> M{fCU3NCVkeHUh?=
SK-LMS-1 NIj0W|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvSb4NKSzVyPUCuN|E1OjlizszN NITBUGhUSU6JRWK=
COLO-741 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33SZ2lEPTB;MD6zNVYyPCEQvF2= MV3TRW5ITVJ?
RPMI-8226 M3S0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH65bGNKSzVyPUCuN|E3PDFizszN NX3tfo9GW0GQR1XS
KM12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jxZmlEPTB;MD6zNVg{KM7:TR?= MnHMV2FPT0WU
NMC-G1 NY\SN2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwM{G4OkDPxE1? MmPFV2FPT0WU
SJRH30 NIL2R|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwM{KwOVIh|ryP NWfvbJJbW0GQR1XS
COR-L105 NYHHdHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvNVJ7UUN3ME2wMlMzOjF6IN88US=> M2DMcnNCVkeHUh?=
IM-9 NVvzOIh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwM{OwNlEh|ryP M{TwfHNCVkeHUh?=
TE-12 NHrUfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S1XmlEPTB;MD6zN|MyPyEQvF2= NIPlWJFUSU6JRWK=
KG-1 NGnPV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjLXVhQUUN3ME2wMlM{PDN{IN88US=> NXn1fYVjW0GQR1XS
U251 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH2R|VqUUN3ME2wMlM{PDV4IN88US=> MUTTRW5ITVJ?
EFO-27 M4qwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;PTWM2OD1yLkOzPVUyKM7:TR?= NVHPT25[W0GQR1XS
EW-24 M4rVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO0SJZKSzVyPUCuN|M6QDRizszN M3TZW3NCVkeHUh?=
SF295 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG1XXBKSzVyPUCuN|M6QTlizszN MoHnV2FPT0WU
MC-IXC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH4XmdKSzVyPUCuN|Q2KM7:TR?= M4fIVHNCVkeHUh?=
NCI-H2405 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW5TWM2OD1yLkO0O|MzKM7:TR?= NYHvXGc5W0GQR1XS
NCI-H2009 Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwM{S3N|kh|ryP NYXlUpJ1W0GQR1XS
LB1047-RCC Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwM{W4NVUh|ryP M1O0NnNCVkeHUh?=
KNS-81-FD NVHSc5FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnw[INKSzVyPUCuN|Y3PjdizszN NUPKeWV6W0GQR1XS
HOP-92 M4Pl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwM{[4N{DPxE1? NFHKfmtUSU6JRWK=
L-428 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF61fGJKSzVyPUCuN|cxOTZizszN NVvidVNPW0GQR1XS
C3A MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvhUoVIUUN3ME2wMlM4Ozd7IN88US=> NWjaZWZLW0GQR1XS
NCI-H1792 NHHF[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwM{e2OVUh|ryP NXHvV2NpW0GQR1XS
HuH-7 NFfRNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknTTWM2OD1yLkO3PVEh|ryP M2W0V3NCVkeHUh?=
AGS NUTu[Vg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLwR|FMUUN3ME2wMlM5PjN6IN88US=> MYDTRW5ITVJ?
HT-1197 M1Sxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH1VGxKSzVyPUCuN|k1PiEQvF2= M3TFWnNCVkeHUh?=
CGTH-W-1 NX7MZ5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPmTWM2OD1yLkO5PVE{KM7:TR?= MnHjV2FPT0WU
KNS-42 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXHNXBKSzVyPUCuOFAxPDVizszN M{DRSXNCVkeHUh?=
HuO-3N1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNECwOVUh|ryP NUXHOpk1W0GQR1XS
VMRC-RCZ M{naR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrkUoZHUUN3ME2wMlQxOzB|IN88US=> MmLlV2FPT0WU
SW954 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3OpNKSzVyPUCuOFA{OzVizszN M4Pkb3NCVkeHUh?=
MES-SA NHTYSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jvPWlEPTB;MD60NFUxPSEQvF2= MXjTRW5ITVJ?
Ca-Ski MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorQTWM2OD1yLkSwOVI1KM7:TR?= NGXsNXpUSU6JRWK=
SW13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3sSHZkUUN3ME2wMlQxPjJ4IN88US=> NI[yZlhUSU6JRWK=
NCI-H1437 NXPPdpV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHMO|NKSzVyPUCuOFA5ODVizszN MWXTRW5ITVJ?
U-118-MG M{W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwNEC5NFQh|ryP NVyzPGNyW0GQR1XS
NCI-H1734 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnmTWM2OD1yLkSyNFE{KM7:TR?= NWP0[o8{W0GQR1XS
HDLM-2 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnBTWM2OD1yLkSyNFM{KM7:TR?= MlLzV2FPT0WU
AU565 NIDpcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDMTWM2OD1yLkSyOFY5KM7:TR?= NETkb5lUSU6JRWK=
FADU MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq3ZoJKSzVyPUCuOFI3PDlizszN Mn3GV2FPT0WU
OS-RC-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XxVGlEPTB;MD60N|A5OyEQvF2= MVTTRW5ITVJ?
CAMA-1 M1L1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNEO2NlYh|ryP NEnXWWZUSU6JRWK=
MONO-MAC-6 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCx[I9jUUN3ME2wMlQ{QDR7IN88US=> M4XoTXNCVkeHUh?=
LB831-BLC MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXSb3lxUUN3ME2wMlQ1OzdzIN88US=> NFnQd2RUSU6JRWK=
SW982 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHpbYhKSzVyPUCuOFQ2OjhizszN NWj4d5NFW0GQR1XS
SCC-3 NUT0NI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXUcHhwUUN3ME2wMlQ1PTd7IN88US=> MoizV2FPT0WU
C32 NXj1fohWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNEWyNlkh|ryP NIfUNmJUSU6JRWK=
BFTC-909 MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljITWM2OD1yLkS1Nlk6KM7:TR?= M4m3d3NCVkeHUh?=
MEG-01 NVfRVnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\STWM2OD1yLkS1N|c{KM7:TR?= NHSx[2FUSU6JRWK=
M14 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln4TWM2OD1yLkS1PVc6KM7:TR?= M{f5bnNCVkeHUh?=
MPP-89 NFTVU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;we3BKSzVyPUCuOFYzPTZizszN M2C3UHNCVkeHUh?=
HCC1937 M2jCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q1W2lEPTB;MD60OlM5PCEQvF2= NG\uXXlUSU6JRWK=
SW837 NEKxNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHTWM2OD1yLkS2O|IzKM7:TR?= MoW0V2FPT0WU
DU-145 NX73TVNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\O[WlEPTB;MD60OlczQSEQvF2= NVTxZmVzW0GQR1XS
LB996-RCC NEfN[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TxSGlEPTB;MD60O|A2PCEQvF2= NFywUm1USU6JRWK=
C8166 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XFWGlEPTB;MD60O|Qh|ryP NWC0Omt1W0GQR1XS
MOLT-4 NVra[2FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr3cmZKSzVyPUCuOFc4OzRizszN MnTNV2FPT0WU
DMS-53 M1;zcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsdlBuUUN3ME2wMlQ4QDB7IN88US=> NFfFfW1USU6JRWK=
TE-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X1d2lEPTB;MD60PFMxPSEQvF2= M2jpRXNCVkeHUh?=
KYSE-520 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\2PGJlUUN3ME2wMlQ5OzR|IN88US=> MoH5V2FPT0WU
Detroit562 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rCOWlEPTB;MD60PFg3KM7:TR?= MWrTRW5ITVJ?
SIMA NI\jSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfRTWM2OD1yLkS5OFE4KM7:TR?= MkfYV2FPT0WU
NCI-H1651 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vYbGlEPTB;MD60PVY4KM7:TR?= NYfXeYMyW0GQR1XS
HCC1599 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwNEm5OVUh|ryP NGD3THJUSU6JRWK=
ABC-1 NULHZ4RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXKRm4{UUN3ME2wMlUxPDl4IN88US=> M1rrPXNCVkeHUh?=
CAL-33 M1\rNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwNUC4OFQh|ryP NXzhRWdsW0GQR1XS
OPM-2 NYDpfYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNUC5N|ch|ryP MWLTRW5ITVJ?
RPMI-7951 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfrTWM2OD1yLkWwPVU4KM7:TR?= MVLTRW5ITVJ?
HT-1080 M{D0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHXNVJKSzVyPUCuOVEyOTlizszN M33URnNCVkeHUh?=
LC4-1 M2nYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rpSWlEPTB;MD61NVQxOyEQvF2= M2\iW3NCVkeHUh?=
OVCAR-3 NVfkUYlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j1cWlEPTB;MD61NVU4KM7:TR?= NF3pUpZUSU6JRWK=
CAPAN-1 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwNUKyPFgh|ryP NUToXokyW0GQR1XS
SK-OV-3 NILId|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNUK0N|Qh|ryP M4LnOHNCVkeHUh?=
HuP-T3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP2PYcyUUN3ME2wMlUzQDJ5IN88US=> NXnwdod7W0GQR1XS
NCI-H838 NITPUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHuenJzUUN3ME2wMlUzQDR7IN88US=> NIXDZ2lUSU6JRWK=
K5 M1L3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljFTWM2OD1yLkWzNlAyKM7:TR?= MY\TRW5ITVJ?
CAL-72 M2LsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNUOzPFch|ryP NV3CU4RuW0GQR1XS
NH-12 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu1dmRuUUN3ME2wMlU{QTV7IN88US=> MoXZV2FPT0WU
SNB75 M1rjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHJTWM2OD1yLkW1O|Mh|ryP NEfQPJRUSU6JRWK=
BPH-1 NVTheZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rHRmlEPTB;MD61OlM1PCEQvF2= MlLqV2FPT0WU
NOMO-1 NVnsXpk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fRUmlEPTB;MD61OlM4OiEQvF2= MkeyV2FPT0WU
G-402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNU[0PVkh|ryP NVriOlNYW0GQR1XS
NCI-H2052 M3HLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrQTWM2OD1yLkW2O|QyKM7:TR?= MX3TRW5ITVJ?
RCM-1 NIX1SmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LSNGlEPTB;MD61O|E3PiEQvF2= M3m4dHNCVkeHUh?=
COR-L279 NFv0SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu0[mdYUUN3ME2wMlU4OTh3IN88US=> Ml2zV2FPT0WU
A253 NFGwSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLV[VZbUUN3ME2wMlU4PTJ3IN88US=> NHq5UZhUSU6JRWK=
SK-MM-2 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rZVmlEPTB;MD61O|Y4QSEQvF2= MWLTRW5ITVJ?
NCI-H1703 M1zMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7zb2tKSzVyPUCuOVk1OjdizszN NV\iRmFKW0GQR1XS
UACC-257 M{ft[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;GTWM2OD1yLkW5OFg4KM7:TR?= M2ewVnNCVkeHUh?=
KALS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwNkCwNVEh|ryP MWHTRW5ITVJ?
ES5 M4\OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnzU3lnUUN3ME2wMlYxPDhizszN M3y2OXNCVkeHUh?=
MHH-CALL-2 M4\FSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTDXnhKSzVyPUCuOlA5QDhizszN MljEV2FPT0WU
ChaGo-K-1 M4Dib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MliyTWM2OD1yLk[xNlI6KM7:TR?= MVnTRW5ITVJ?
TGBC1TKB NYLiV5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j0WGlEPTB;MD62NVk5KM7:TR?= NF;FOYJUSU6JRWK=
KU-19-19 NVXt[GlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LxT2lEPTB;MD62OFU5PiEQvF2= NV;2XnBtW0GQR1XS
COLO-684 M4fuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\Je2lEPTB;MD62OVYyOSEQvF2= MVzTRW5ITVJ?
LS-1034 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnSdVVLUUN3ME2wMlY2QDF7IN88US=> M1u1S3NCVkeHUh?=
RT-112 NWW3SHFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2yTWM2OD1yLk[2OVg4KM7:TR?= NFLtW3lUSU6JRWK=
Capan-2 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNk[2NlIh|ryP NW\FNYpTW0GQR1XS
HSC-4 NXW0SIZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNk[2PVgh|ryP MV7TRW5ITVJ?
COLO-824 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPsc2FyUUN3ME2wMlY4QDJ|IN88US=> NFPqfIFUSU6JRWK=
NCI-H2170 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwNkiyOVgh|ryP NEPheohUSU6JRWK=
GDM-1 NFm4U29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGx[ZhKSzVyPUCuOlg1QTRizszN M3:0S3NCVkeHUh?=
KP-4 NX63fGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki0TWM2OD1yLk[5OVc{KM7:TR?= NFfhbpRUSU6JRWK=
VA-ES-BJ MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ewVGlEPTB;MD62PVk5PiEQvF2= NHfIVHdUSU6JRWK=
KM-H2 NVLvV2NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnyxTWM2OD1yLkewNFkyKM7:TR?= NEfk[VBUSU6JRWK=
HH M1Sxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3pTWM2OD1yLkewOlYzKM7:TR?= NHrBW|NUSU6JRWK=
DK-MG NGDQOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvCfo9oUUN3ME2wMlcyODF4IN88US=> NG[0VlhUSU6JRWK=
VM-CUB-1 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:1PVBKUUN3ME2wMlcyOjV7IN88US=> MVvTRW5ITVJ?
COLO-829 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwN{G5PFUh|ryP NHfTV4xUSU6JRWK=
OMC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPxTWM2OD1yLkeyNVA1KM7:TR?= NGrTR4lUSU6JRWK=
NB12 NWrzb|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT6fJFKSzVyPUCuO|I2ODRizszN M1L5NnNCVkeHUh?=
NCI-H28 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrUUWlKSzVyPUCuO|QxQDNizszN MlrDV2FPT0WU
A673 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknCTWM2OD1yLke1NVc4KM7:TR?= MWPTRW5ITVJ?
LB2241-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm5PFRKSzVyPUCuO|YxQDdizszN NFq2UoJUSU6JRWK=
CCRF-CEM NW\Sbpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtNng3UUN3ME2wMlc4ODV{IN88US=> M{TO[3NCVkeHUh?=
NCI-H510A M2nLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD0TWM2OD1yLke3NVg3KM7:TR?= MkLVV2FPT0WU
SW48 NULRcotvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwN{ezN|Mh|ryP NIfDTpJUSU6JRWK=
NCI-H2081 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HEXGlEPTB;MD63PFE1PyEQvF2= M4P6SXNCVkeHUh?=
RMG-I MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxfoJKSzVyPUCuO|gzOTJizszN M364VHNCVkeHUh?=
LU-99A MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGyU4lKSzVyPUCuO|g1OTNizszN MUnTRW5ITVJ?
KP-N-YS NXT0fI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HKNGlEPTB;MD63PFkzOSEQvF2= MlHHV2FPT0WU
MDA-MB-231 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXsSGZKSzVyPUCuPFAyOzFizszN NIrNZlBUSU6JRWK=
U031 NHTkPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S1UWlEPTB;MD64NVQzOyEQvF2= NFHj[IZUSU6JRWK=
EVSA-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXIW3FKSzVyPUCuPFE3PzJizszN NVTNXYdGW0GQR1XS
MDA-MB-157 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vSfmlEPTB;MD64NlI4OSEQvF2= MYDTRW5ITVJ?
EHEB M{WweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm5WZpKSzVyPUCuPFIzPzZizszN MkPBV2FPT0WU
KINGS-1 M3SzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL4TWM2OD1yLkiyOVU2KM7:TR?= NX7tTlZ5W0GQR1XS
23132-87 NFLDdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLkTWM2OD1yLkiyPFQ{KM7:TR?= NVi4dVVpW0GQR1XS
EFO-21 M2rH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXuSopIUUN3ME2wMlg1ODh7IN88US=> M{LoeXNCVkeHUh?=
DOK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrwe5BKSzVyPUCuPFQ5KM7:TR?= Mn;aV2FPT0WU
NCI-H2171 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwOES5OkDPxE1? MUDTRW5ITVJ?
NCI-SNU-5 NIj4XJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwOEW1O{DPxE1? Ml;OV2FPT0WU
SK-N-DZ NWXKR4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwOEW5OFMh|ryP NVjqRoZkW0GQR1XS
SNU-C2B NEXzO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTZTWM2OD1yLki2PFAyKM7:TR?= MUTTRW5ITVJ?
CP66-MEL NXvJVGgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq4fIpKSzVyPUCuPFcyOSEQvF2= MXrTRW5ITVJ?
SN12C NVrUUWJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwOEi2N|ch|ryP NV\WT|hvW0GQR1XS
A172 M1TEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jU[mlEPTB;MD64PFY6QCEQvF2= NVvXS3RJW0GQR1XS
NCI-H2347 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofzTWM2OD1yLki4O|U{KM7:TR?= M3rU[nNCVkeHUh?=
NCI-H2228 NF\DeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn0SodKSzVyPUCuPFk{OzlizszN MkTCV2FPT0WU
SNU-387 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDNdVFKSzVyPUCuPVAzPjRizszN MXXTRW5ITVJ?
SK-MEL-24 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHIOXRKSzVyPUCuPVE{PDRizszN MYnTRW5ITVJ?
MDA-MB-468 NED2fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVziOW9EUUN3ME2wMlkyPzNizszN NX73T2xzW0GQR1XS
NCI-H1694 M1m3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm3eFBDUUN3ME2wMlkyQDd4IN88US=> NF;DXIhUSU6JRWK=
CCF-STTG1 NHLlZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:zTWM2OD1yLkmyOlM4KM7:TR?= M2XqeXNCVkeHUh?=
K052 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwOUSwOFch|ryP NIHKZYFUSU6JRWK=
NCI-H446 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu2[FJKSzVyPUCuPVUxOSEQvF2= MnPiV2FPT0WU
MFE-280 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnaTWM2OD1yLkm2NlkyKM7:TR?= NFyxT4xUSU6JRWK=
KU812 NUPuco9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TrXmlEPTB;MD65PVM5QSEQvF2= M2PFfHNCVkeHUh?=
MDA-MB-361 M2W5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7XdoZKSzVyPUCuPVk4PzdizszN NGPUOIdUSU6JRWK=
Raji MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnexTWM2OD1zLkCyNlY4KM7:TR?= NHjuW4RUSU6JRWK=
TE-6 NIDxb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHJTWM2OD1zLkCzOVY3KM7:TR?= NWqwWGV1W0GQR1XS
CAL-148 NHz5dZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPYRXNsUUN3ME2xMlA1PDR|IN88US=> NUjlcZJpW0GQR1XS
NCI-H1963 NXfOeVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMES1OVMh|ryP MmC4V2FPT0WU
SK-N-AS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PCVmlEPTB;MT6wOFY5PSEQvF2= NHfk[WtUSU6JRWK=
RERF-LC-MS Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[wbGlEPTB;MT6wOlM1QSEQvF2= MWrTRW5ITVJ?
BEN NVPDdm9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHS[HVKSzVyPUGuNFcyOzdizszN MojUV2FPT0WU
CAS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LRTGlEPTB;MT6wPVEzOyEQvF2= M{Xjd3NCVkeHUh?=
SW780 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLtTGtNUUN3ME2xMlA6OThzIN88US=> MX3TRW5ITVJ?
LU-65 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17r[GlEPTB;MT6wPVQyKM7:TR?= MYHTRW5ITVJ?
D-283MED MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PmXmlEPTB;MT6xNlI4OiEQvF2= MmPqV2FPT0WU
HCC2157 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwMUO2OFIh|ryP MlvoV2FPT0WU
RCC10RGB NU\WZm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXznSZJbUUN3ME2xMlE1ODB4IN88US=> NH7zVYlUSU6JRWK=
PLC-PRF-5 M3rtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXINohKSzVyPUGuNVUzOjlizszN MXXTRW5ITVJ?
H4 M1rmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL5R45KSzVyPUGuNVU1OzlizszN MU\TRW5ITVJ?
TUR M3rrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwMUW3OVIh|ryP M4jYPHNCVkeHUh?=
NCI-H2141 NUTKSVM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTwN5VKSzVyPUGuNVg6PDZizszN MoizV2FPT0WU
PFSK-1 NVPHWmV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzsXHFKSzVyPUGuNlA2OzJizszN MWDTRW5ITVJ?
SK-MEL-28 NX3MW4ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPCVG1FUUN3ME2xMlI{OjJzIN88US=> MojSV2FPT0WU
SCC-9 NXPDV2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvST3ZKSzVyPUGuNlM3PjVizszN MU\TRW5ITVJ?
T47D MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;OTWM2OD1zLkKzOlk3KM7:TR?= MYXTRW5ITVJ?
TCCSUP M{Pq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjqZmtKSzVyPUGuNlUxOjlizszN Ml;WV2FPT0WU
SU-DHL-1 M3\ZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwMkWxNVgh|ryP NH7rPVhUSU6JRWK=
HL-60 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzHTWM2OD1zLkK1OVg5KM7:TR?= M{nPVnNCVkeHUh?=
NCI-H1436 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLGepRyUUN3ME2xMlI3OTR7IN88US=> MVXTRW5ITVJ?
DMS-114 NGnhXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LxdWlEPTB;MT6yOlY{OiEQvF2= NEnJWo9USU6JRWK=
BOKU MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwMkiwPVUh|ryP NUTGSG9{W0GQR1XS
MS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInTd2dKSzVyPUGuNlkxPjlizszN M3LEfHNCVkeHUh?=
NCI-H661 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfnbWRKSzVyPUGuN|A1PzhizszN NWW5dFNsW0GQR1XS
HT-3 M4K5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zIXGlEPTB;MT6zNFUzQSEQvF2= MlK1V2FPT0WU
CAL-54 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jIemlEPTB;MT6zNFczPSEQvF2= MlzUV2FPT0WU
SW1463 M4fRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XK[2lEPTB;MT6zNVg4OiEQvF2= NFTtXIpUSU6JRWK=
COLO-668 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXPVXdKSzVyPUGuN|MxPTZizszN Mn;JV2FPT0WU
PANC-08-13 NFvYT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrsbpRIUUN3ME2xMlM{QDB|IN88US=> NVjFcGZRW0GQR1XS
BB49-HNC NHH4UVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TNWmlEPTB;MT6zOFAyKM7:TR?= NVr0T5RVW0GQR1XS
M059J MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwM{W4N|Ih|ryP M4nZNXNCVkeHUh?=
NCCIT NGDoWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fsZWlEPTB;MT6zO|k5QCEQvF2= M3HPXXNCVkeHUh?=
LN-405 NHjoVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf5b|FlUUN3ME2xMlM6OjZ2IN88US=> Mle4V2FPT0WU
UMC-11 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTOTWM2OD1zLkO5PVk3KM7:TR?= NIXLc5BUSU6JRWK=
NB5 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iwSGlEPTB;MT60NVIzPyEQvF2= MVrTRW5ITVJ?
TE-441-T Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\UTWM2OD1zLkSyPFE4KM7:TR?= MlzYV2FPT0WU
ME-180 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwNESzPVIh|ryP M{PBVXNCVkeHUh?=
HCC70 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjT[HJZUUN3ME2xMlQ3ODl4IN88US=> NELVeGdUSU6JRWK=
no-10 NIXqNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwNE[xPFEh|ryP MnnLV2FPT0WU
JEG-3 NH6xNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX0RlZKSzVyPUGuOVAyOzJizszN NV7VZpR4W0GQR1XS
no-11 M2rNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwNUC4PFIh|ryP MojHV2FPT0WU
CHP-126 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwNU[2PVEh|ryP NIPldFhUSU6JRWK=
EGI-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDVR5REUUN3ME2xMlU5ODJ3IN88US=> MWnTRW5ITVJ?
D-392MG MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;mTWM2OD1zLkW5OlMh|ryP MljtV2FPT0WU
RT4 M2fyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PwVWlEPTB;MT61PVY{PyEQvF2= MUDTRW5ITVJ?
A204 M3vaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwNUm4NFEh|ryP MoKxV2FPT0WU
NCI-H1304 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwNkO1PVEh|ryP NES2SXlUSU6JRWK=
Becker NWP6PI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwNkSyOFEh|ryP MW\TRW5ITVJ?
OE19 M{Trb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjKTWM2OD1zLk[1OVE5KM7:TR?= NXXabFhxW0GQR1XS
EKVX NV62UXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDtTWM2OD1zLk[1OlE5KM7:TR?= MXzTRW5ITVJ?
KLE M{PEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvp[2NKSzVyPUGuOlU4OTRizszN M{HESnNCVkeHUh?=
K-562 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYju[JVrUUN3ME2xMlY4ODN5IN88US=> NV\CeW9PW0GQR1XS
MDA-MB-175-VII M1e3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTCOJJKSzVyPUGuOlg6QTdizszN M3XoW3NCVkeHUh?=
NCI-H716 NV;FWI5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XyfmlEPTB;MT62PVMxPCEQvF2= NGHLUGpUSU6JRWK=
Caov-3 NGnTZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwNkm0NVMh|ryP NEe5O|VUSU6JRWK=
HCC1187 M3uwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwN{C1OFUh|ryP NF\XdXBUSU6JRWK=
CAKI-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4flTGlEPTB;MT63NlI6OiEQvF2= NXix[|FyW0GQR1XS
MOLT-16 NU\rR|FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHITWM2OD1zLkezN|A4KM7:TR?= M1S2cnNCVkeHUh?=
PC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknqTWM2OD1zLke1NFgh|ryP M{LwcXNCVkeHUh?=
DV-90 M3fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwN{W1PFUh|ryP NGL2TpVUSU6JRWK=
RXF393 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7NbWFmUUN3ME2xMlc4Ojl2IN88US=> NUDJWXI4W0GQR1XS
SK-NEP-1 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjPVIpKSzVyPUGuPFI{OzlizszN MV;TRW5ITVJ?
HCC1419 M{H2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fVRWlEPTB;MT64NlY6OiEQvF2= NH62foVUSU6JRWK=
BV-173 NGPnSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwOEK5PVUh|ryP MlrPV2FPT0WU
MKN7 NYXQPWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS1TWM2OD1zLki5NlIh|ryP M3OyRXNCVkeHUh?=
LAN-6 NHj2b2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLPZ3llUUN3ME2xMlg6PTV|IN88US=> M2flTnNCVkeHUh?=
Mo-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j0R2lEPTB;MT65NFA{QSEQvF2= MVvTRW5ITVJ?
HCC1395 NUnMWGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF21c|VKSzVyPUGuPVI5PjNizszN NIrDeoxUSU6JRWK=
HC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHzdVVKSzVyPUGuPVM1PyEQvF2= NHj5R4ZUSU6JRWK=
HPAF-II MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPFRo5NUUN3ME2xMlk1PDF6IN88US=> MkezV2FPT0WU
CPC-N NGSybpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwOUiwNFIh|ryP NHPUc4dUSU6JRWK=
MKN45 NVjDUmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwOUmxNVkh|ryP NIPuSZNUSU6JRWK=
NCI-H1693 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLOTWM2OD1{LkCwOFM{KM7:TR?= NULZZWx2W0GQR1XS
SHP-77 NFPaOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvrTWM2OD1{LkCwOVM{KM7:TR?= NHr0SJNUSU6JRWK=
NCI-H1522 NX\heHFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHrO5drUUN3ME2yMlAyPzJ2IN88US=> MVfTRW5ITVJ?
SW1573 M3XJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrkPHdEUUN3ME2yMlAzOiEQvF2= NEjpS|JUSU6JRWK=
DBTRG-05MG NWPwc|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP6TWM2OD1{LkC2NFg4KM7:TR?= M1rqeXNCVkeHUh?=
SCC-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPZOGtCUUN3ME2yMlE1OzFizszN M1z5dnNCVkeHUh?=
DMS-153 NX\aWpNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\sbFExUUN3ME2yMlE3PjZ6IN88US=> M1SxSXNCVkeHUh?=
MDA-MB-415 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwMUe1NkDPxE1? MofSV2FPT0WU
NCI-H2126 NVHyRYZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;BPFVKSzVyPUKuNlI5QDhizszN NEX4TW9USU6JRWK=
MDA-MB-453 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu0dopKSzVyPUKuNlM{OiEQvF2= M2DpSnNCVkeHUh?=
U-87-MG NGP1PHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS1VpZwUUN3ME2yMlI5PTl{IN88US=> M4nyNXNCVkeHUh?=
LNCaP-Clone-FGC NIe2XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwM{CxNFIh|ryP M3TqO3NCVkeHUh?=
NCI-H1581 NXvxUJAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjz[XpKSzVyPUKuN|IyODVizszN M3K3[HNCVkeHUh?=
BC-3 NI[zOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3bWlEPTB;Mj6zOlUxQSEQvF2= NHvhZmlUSU6JRWK=
HCC38 NIfKb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTrWYFQUUN3ME2yMlM5PDR5IN88US=> MWjTRW5ITVJ?
HCC2218 NH6yTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInRbGlKSzVyPUKuOFA5ODlizszN NWTHcHBIW0GQR1XS
RO82-W-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwNEGyOUDPxE1? MUTTRW5ITVJ?
C2BBe1 NXnWUJVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILoTYZKSzVyPUKuOFE2PzhizszN Mmi2V2FPT0WU
LAMA-84 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrmTmNYUUN3ME2yMlU4OzZ6IN88US=> MXPTRW5ITVJ?
GMS-10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D2O2lEPTB;Mj61O|YyOSEQvF2= MnHWV2FPT0WU
GCT NXrqc|FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPc2lEPTB;Mj61PFY6PCEQvF2= MkLtV2FPT0WU
SK-CO-1 NV7a[I15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwNkG2OkDPxE1? NXz6XXhZW0GQR1XS
NCI-H526 NH\2TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rmXGlEPTB;Mj62N|Q2KM7:TR?= NV3LXGtvW0GQR1XS
SW1088 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XNS2lEPTB;Mj63O|g{QSEQvF2= M{HPOHNCVkeHUh?=
HT55 NV7qNpIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L4ZmlEPTB;Mj63PFY6PSEQvF2= NWjjU4xLW0GQR1XS
NB10 NE\1[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HubmlEPTB;Mj64NVc1QCEQvF2= NIXEb2FUSU6JRWK=
UACC-893 NIfwUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX0TWM2OD1{Lki1O|Q6KM7:TR?= M4r2enNCVkeHUh?=
NCI-H1618 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3ZXVKSzVyPUKuPFgyPTNizszN M2LsUXNCVkeHUh?=
NCI-H1092 NG\INpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwMEe4NVIh|ryP MkjEV2FPT0WU
SBC-1 M1rjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7EV3pKSzVyPUOuNFg2PTNizszN NUTFPXdRW0GQR1XS
NCI-H1623 NFTuXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwMEmzOEDPxE1? MUHTRW5ITVJ?
SiHa MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nKfGlEPTB;Mz6xNVk4PyEQvF2= MoXuV2FPT0WU
D-263MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPsTWM2OD1|LkG0O|g5KM7:TR?= M3njb3NCVkeHUh?=
NCI-H1573 NWjl[JMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXmWW9KSzVyPUOuNVk3PDFizszN M3iyT3NCVkeHUh?=
NCI-H82 MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvQTnlWUUN3ME2zMlM1PDN7IN88US=> NITWc4JUSU6JRWK=
NCI-H2196 M4Dp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyVJZKSzVyPUOuN|UxODhizszN M4D2N3NCVkeHUh?=
MFM-223 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNwM{ezOVEh|ryP NVnKdXR6W0GQR1XS
COLO-678 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNwM{ixPFYh|ryP NF3RfmZUSU6JRWK=
EW-3 NX25VIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfk[25DUUN3ME2zMlQxQTVizszN MlPZV2FPT0WU
MHH-NB-11 NV30OYRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTX[o1KSzVyPUOuOFQxPjlizszN NGq2dm9USU6JRWK=
EM-2 M1PMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnnOVBKSzVyPUOuOlM6QCEQvF2= MlfrV2FPT0WU
FTC-133 M2jMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3lOIRKSzVyPUOuOlU1PThizszN MoXoV2FPT0WU
NCI-H209 M{LHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwNke2OVMh|ryP MUHTRW5ITVJ?
TGBC24TKB NY[xR5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwNkizOVUh|ryP MXnTRW5ITVJ?
LC-1F MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfaSWVHUUN3ME2zMlcyPzZ2IN88US=> NV3nV2REW0GQR1XS
C-4-II NFf5T|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\NemlEPTB;Mz63OVY1OyEQvF2= MV7TRW5ITVJ?
NCI-H1650 M2rVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f3[2lEPTB;Mz63PFQ2PSEQvF2= NIrSeHhUSU6JRWK=
JVM-2 M1npW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXTUYFqUUN3ME2zMlk{PjN7IN88US=> NE\yWXBUSU6JRWK=
CaR-1 M2DBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNwOUe2NVch|ryP MV;TRW5ITVJ?
MDA-MB-134-VI NVK5SFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP5NldKSzVyPUSuNFI6PTJizszN M1;DTHNCVkeHUh?=
NCI-H719 M1i5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTPTWM2OD12LkG1N|g5KM7:TR?= MU\TRW5ITVJ?
GOTO NVPYS2F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTKRoFKSzVyPUSuNlk4ODVizszN MX3TRW5ITVJ?
NCI-N87 M4P6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX22e|dTUUN3ME20MlM5QDJzIN88US=> NVn4c5RVW0GQR1XS
NB6 NFLMZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6yTWM2OD12LkSyOVA6KM7:TR?= MlvlV2FPT0WU
DSH1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj0TWM2OD12LkS3NVE3KM7:TR?= MkXHV2FPT0WU
BT-20 M1nXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TsOGlEPTB;ND60PVAxOiEQvF2= NFTpR3RUSU6JRWK=
NCI-H1882 M2nsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTdWlEPTB;ND61NFU4KM7:TR?= Mn3LV2FPT0WU
WM-115 NX;IeWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTaSJpKSzVyPUSuOVA5QDFizszN M3zZeHNCVkeHUh?=
SKG-IIIa MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fO[WlEPTB;ND62O|c4KM7:TR?= NW\5[lhZW0GQR1XS
NCI-H69 NHnjfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwN{CyO|Uh|ryP NXH2T2llW0GQR1XS
MSTO-211H NV;ic2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LRpZ2UUN3ME20Mlg{PTZ3IN88US=> NEXnNpFUSU6JRWK=
Mewo M{LLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK2e3NzUUN3ME20Mlk3OzF|IN88US=> MUDTRW5ITVJ?
GI-ME-N NFjEfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDs[JJKSzVyPUWuNFA2ODlizszN NYnEWIFrW0GQR1XS
T98G NVLKN|dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwME[1NFgh|ryP NInq[YdUSU6JRWK=
ECC4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTVwMEmzO|Ih|ryP NXLpfFV4W0GQR1XS
EW-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm3V|lKSzVyPUWuNVgxQTlizszN NVXyPJk1W0GQR1XS
COLO-800 NV3LXW1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTpTWM2OD13LkG5N|Q6KM7:TR?= MnXlV2FPT0WU
NCI-H1755 NHPTNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LDPGlEPTB;NT6yN|AzPyEQvF2= NVvPe3hGW0GQR1XS
KMS-12-PE MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrwTWM2OD13LkO1NFg2KM7:TR?= MXXTRW5ITVJ?
HCC1954 NWjMUYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnYSFZGUUN3ME21Mlg2QTdzIN88US=> MXvTRW5ITVJ?
NCI-H187 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwOUK5PFkh|ryP NFnMcYhUSU6JRWK=
LU-165 NFfmOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULFcmdTUUN3ME21Mlk6ODB{IN88US=> NV3Wd5NwW0GQR1XS
YAPC M3OwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTCfXhKSzVyPUWuPVkxPjhizszN NVPDWnVQW0GQR1XS
LU-139 NIj6cmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XWUGlEPTB;Nj6wPFM3QCEQvF2= MnW5V2FPT0WU
D-502MG NV6xeXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZwM{KwOFch|ryP M4nNTHNCVkeHUh?=
IST-SL1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfDUVNwUUN3ME22MlU{QTR6IN88US=> NY\sc3R[W0GQR1XS
DG-75 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HFPGlEPTB;Nj64PFc5PiEQvF2= MWTTRW5ITVJ?
NCI-H1155 NXPnUJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zNUWlEPTB;Nj65OVU5OSEQvF2= M4jwbHNCVkeHUh?=
EFE-184 M1XMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTdwM{G2PVUh|ryP NGP3RppUSU6JRWK=
AsPC-1 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7xR3RKSzVyPUeuOFg5ODdizszN MVrTRW5ITVJ?
SW948 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjyTnhoUUN3ME23MlU5Ozl3IN88US=> NF36fI9USU6JRWK=
NCI-H524 NYPCfoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6[XBKSzVyPUmuOVg3OjhizszN MX;TRW5ITVJ?
KOSC-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzNc|VKSzVyPUmuOlI5OzRizszN M1z6NXNCVkeHUh?=
T-24 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\JTWM2OD17Lkm0OFE2KM7:TR?= MX3TRW5ITVJ?
NCI-H748 NYH2dpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFyLk[zPVch|ryP M2HZTnNCVkeHUh?=
NCI-H23 M1LGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHFUYdTUUN3ME2xNE43PDR{IN88US=> Ml3mV2FPT0WU
UACC-812 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1zMT63NVch|ryP MVjTRW5ITVJ?
SCLC-21H MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37nc2lEPTB;MUKuNVU2OSEQvF2= NH;rOHVUSU6JRWK=
NCI-SNU-16 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:wTWM2OD1zMz6xNlU5KM7:TR?= NYnrXVJ5W0GQR1XS
HD-MY-Z NVPkb2hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPaNVhKSzVyPUG0MlY{PjNizszN MVHTRW5ITVJ?
SK-N-FI MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS3d3A1UUN3ME2xOE45QTF{IN88US=> MknLV2FPT0WU
LB647-SCLC NGTIUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF3LkexPVUh|ryP NWfyNmFrW0GQR1XS
NCI-H345 NYfkUI45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rqbWlEPTB;MUeuN|Q{KM7:TR?= MoXvV2FPT0WU
NCI-H1563 NIP4empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W4RmlEPTB;MUiuO|YxOSEQvF2= MnuzV2FPT0WU
RL Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPPN3BKSzVyPUKxMlI3PTZizszN NWHV[JF3W0GQR1XS
KY821 M1W1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvvTWM2OD1{Mj6wOVU{KM7:TR?= M2[4d3NCVkeHUh?=
JVM-3 NIriOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2npWmlEPTB;MkWuNFQyOyEQvF2= MUfTRW5ITVJ?
NCI-H1793 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ6LkW0PVkh|ryP NX\xO5VHW0GQR1XS
LU-134-A MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfqXYtlUUN3ME2zNE4zODN5IN88US=> MVnTRW5ITVJ?
NCI-H1395 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u0XmlEPTB;M{KuNlQ{OSEQvF2= M3fVcnNCVkeHUh?=
NCI-H1993 NXTiSZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMSodTUUN3ME2zNk45OjF6IN88US=> NYHWOZp2W0GQR1XS
P31-FUJ M162WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLZTWM2OD1|Mz60PFk6KM7:TR?= NXO0cmNLW0GQR1XS
LS-513 NVrlN5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fQVWlEPTB;M{WuPFg4QSEQvF2= MUnTRW5ITVJ?
SK-MEL-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j6O2lEPTB;NECuN|Q6QSEQvF2= M4q1bHNCVkeHUh?=
SW684 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PYb2lEPTB;NEOuPVY3OSEQvF2= NG\0dZVUSU6JRWK=
COR-L88 NFnBSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHntZVJKSzVyPUS0MlA3PjVizszN NGTCTFlUSU6JRWK=
NCI-H889 NYrhUHB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L6bmlEPTB;NEWuNFA5PyEQvF2= MULTRW5ITVJ?
TALL-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LOUmlEPTB;NE[uNVE6QSEQvF2= NFj2Z5JUSU6JRWK=
KARPAS-299 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR5LkG5PVMh|ryP M3\aVHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2
NCT00724841 Terminated Metastatic Melanoma Gemin X|Teva Pharmaceutical Industries June 2008 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID